Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Infectious disease

HIV/AIDS

CD4; HIV gp120

In vitro studies suggest bispecific antibodies targeting CD4 and gp120 could be useful for treating HIV infection. In a viral neutralization assay, bispecific mAbs engineered to recognize both CD4 and gp120 had better potency than the CD4-specific parent mAb ibalizumab. Next steps include preclinical development of the bispecific antibodies as passive immunotherapy for HIV.
In 2007, TaiMed Biologics Inc. licensed ibalizumab from Genentech Inc., now a unit of Roche.

SciBX 6(34); doi:10.1038/scibx.2013.929
Published online Sept. 5, 2013

Patent pending; licensed to TaiMed Biologics

Pace, C.S. et al. Proc. Natl. Acad. Sci. USA; published online July 22, 2013;
doi:10.1073/pnas.1304985110
Contact: David D. Ho,
The Rockefeller University, New York, N.Y.
e-mail:
dho@adarc.org